Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the
patients treated since then are probably numbered in the millions. Fifty to 90% of …

The procedure guideline for radioiodine therapy (RIT) of differentiated thyroid cancer
(version 3) is the counterpart to the procedure guideline for 131 I whole-body scintigraphy …

Aim: This study was performed to determine the results of ablative radioiodine therapy (RIT)
when the achieved dose in the thyroid was above 200 Gy and to characterize predictive …

Aim: The clinical relevance of thyroidal autonomy, ie the risk of a patient to become
hyperthyroid after exposure to iodine, can be estimated by measurement of the thyroidal …

Background: The importance of restricting iodine intake to increase thyroid uptake of 131I is
well-known, but its minimum duration is not clear. The present study aimed at determining …

Version 3 of the procedure guideline for 131 I whole-body scintigraphy (WBS) is the
counterpart to the procedure guideline for radioiodine therapy (version 3) and specify the …

Purpose In radioiodine therapy the “stunning phenomenon” is defined as a reduction of
radioiodine uptake after diagnostic application of 131 I. In the current study, we established …

Objective Consuming a low-iodine diet (LID) is a widely accepted practice before
administering radioiodine (131I) to evaluate and to treat thyroid disease. Although this …

Abstract Purpose 124 I-PET/CT can be used for pre-therapeutic assessment of radioactive
iodine uptake in benign thyroid disorders, however systematic comparisons with intra …

Background: Radioiodine uptake (RIU) is one of the main prognostic factors for curative
results of radioiodine therapy in patients with differentiated thyroid cancer. Some days after …